Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
preSAVE: Bladder Preservation with Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer
2024-516943-14-01Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan and zimberelimab in muscle-invasive bladder carcinoma (MIBC), transitional cell carcinoma (TCC) and bladder squamous cell carcinoma, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Event-free survival. Planned start Oct 2025; status: authorised.
02
Drugs
sacituzumab govitecanzimberelimab
03
Conditions
muscle-invasive bladder carcinoma (MIBC)transitional cell carcinoma (TCC)bladder squamous cell carcinoma
Beyond the preview
Go deeper on 2024-516943-14-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516943-14-01.